Neutrophils and Activated Macrophages Control Mucosal Immunity by Proteolytic Cleavage of Antileukoproteinase
暂无分享,去创建一个
G. Opdenakker | P. Proost | J. Vandooren | A. A. Abu El-Asrar | V. Rybakin | P. Goeminne | E. Ugarte-Berzal | L. Boon
[1] M. Suyama,et al. Identification of Secretory Leukoprotease Inhibitor As an Endogenous Negative Regulator in Allergic Effector Cells , 2017, Front. Immunol..
[2] C. Overall,et al. New intracellular activities of matrix metalloproteinases shine in the moonlight. , 2017, Biochimica et biophysica acta. Molecular cell research.
[3] G. Opdenakker,et al. Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1 , 2017, Haematologica.
[4] G. Salvesen,et al. Toolbox of Fluorescent Probes for Parallel Imaging Reveals Uneven Location of Serine Proteases in Neutrophils. , 2017, Journal of the American Chemical Society.
[5] S. Vermeire,et al. Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease , 2017, Nature Communications.
[6] J. Mainz,et al. Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy , 2015, Mediators of inflammation.
[7] J. Mainz,et al. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[8] S. Moestrup,et al. Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. , 2015, The Biochemical journal.
[9] S. Seys,et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis , 2014, Respirology.
[10] P. E. Van den Steen,et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.
[11] A. Dufour,et al. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. , 2013, Trends in pharmacological sciences.
[12] G. Opdenakker,et al. Zymography methods for visualizing hydrolytic enzymes , 2013, Nature Methods.
[13] Geoffrey I. Webb,et al. PROSPER: An Integrated Feature-Based Tool for Predicting Protease Substrate Cleavage Sites , 2012, PloS one.
[14] K. Welte,et al. PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS A lack of secretory leukocyte protease inhibitor ( SLPI ) causes defects in granulocytic differentiation , 2014 .
[15] J. Clancy,et al. Human Neutrophil Elastase-Mediated Cleavage Sites of MMP-9 and TIMP-1: Implications to Cystic Fibrosis Proteolytic Dysfunction , 2010, Molecular medicine.
[16] Paul McNally,et al. Decreased Levels of Secretory Leucoprotease Inhibitor in the Pseudomonas-Infected Cystic Fibrosis Lung Are Due to Neutrophil Elastase Degradation1 , 2009, The Journal of Immunology.
[17] M. D'Andrea,et al. Cleaved SLPI, a novel biomarker of chymase activity , 2008, Biological chemistry.
[18] J. Cowland,et al. The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils , 2008, Journal of leukocyte biology.
[19] P. E. Van den Steen,et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. , 2007, Biochimica et biophysica acta.
[20] A. Ding,et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI , 2007, Nature Immunology.
[21] R. Dwek,et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.
[22] Carl Nathan,et al. Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.
[23] A. Ding,et al. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. , 2005, Biochimica et biophysica acta.
[24] J. Sallenave,et al. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. , 2005, American journal of respiratory cell and molecular biology.
[25] Kutty Selva Nandakumar,et al. Antileukoproteinase: Modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis , 2004, Arthritis & Rheumatism.
[26] M. Stack,et al. Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Husson,et al. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. , 2003, Biochemical and biophysical research communications.
[28] J. Miyazaki,et al. Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice , 2003, The Journal of experimental medicine.
[29] H. Erdjument-Bromage,et al. Conversion of Proepithelin to Epithelins Roles of SLPI and Elastase in Host Defense and Wound Repair , 2002, Cell.
[30] N. McElvaney,et al. Secretory Leucoprotease Inhibitor Prevents Lipopolysaccharide-induced IκBα Degradation without Affecting Phosphorylation or Ubiquitination* , 2002, The Journal of Biological Chemistry.
[31] R. Levine,et al. Cathepsin B, L, and S Cleave and Inactivate Secretory Leucoprotease Inhibitor* , 2001, The Journal of Biological Chemistry.
[32] R. Stockley,et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD , 2001, Thorax.
[33] P. E. Van den Steen,et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.
[34] A. Kulkarni,et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing , 2000, Nature Medicine.
[35] J. Sallenave. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease , 2000, Respiratory research.
[36] Fenyu Jin,et al. Secretory Leukocyte Protease Inhibitor Interferes with Uptake of Lipopolysaccharide by Macrophages , 1999, Infection and Immunity.
[37] S. Wahl,et al. Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall–Induced Arthritis , 1999, The Journal of experimental medicine.
[38] J. Sallenave,et al. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils , 1997, Journal of leukocyte biology.
[39] J. Cowland,et al. Granules of the human neutrophilic polymorphonuclear leukocyte. , 1997, Blood.
[40] S. Wahl,et al. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. , 1997, The Journal of clinical investigation.
[41] D. Radzioch,et al. Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide , 1997, Cell.
[42] G. Ferry,et al. Activation of MMP‐9 by neutrophil elastase in an in vivo model of acute lung injury , 1997, FEBS letters.
[43] G. Steffens,et al. Antibacterial activity of antileukoprotease , 1996, Infection and immunity.
[44] T. Suga,et al. Pharmacological activity of the C‐terminal and N‐terminal domains of secretory leukoprotease inhibitor in vitro , 1995, British journal of pharmacology.
[45] J. Hoidal,et al. Interaction of secretory leukocyte protease inhibitor with proteinase-3. , 1993, American journal of respiratory cell and molecular biology.
[46] P. Renesto,et al. Inhibition by recombinant SLPI and half‐SLPI (Asn55‐Ala107) of elastase and cathepsin G activities: consequence for neutrophil‐platelet cooperation , 1993, British journal of pharmacology.
[47] H. Boushey,et al. Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases. , 1992, The American review of respiratory disease.
[48] G. Opdenakker,et al. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. , 1991, European journal of biochemistry.
[49] M. T. Brewer,et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. , 1991, The Journal of clinical investigation.
[50] R. Crystal,et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. , 1991, The Journal of clinical investigation.
[51] J. Dijkman,et al. Tissue distribution of antileukoprotease and lysozyme in humans. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[52] R. Huber,et al. The 2.5 A X‐ray crystal structure of the acid‐stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha‐chymotrypsin. , 1988, The EMBO journal.
[53] A. Krüger,et al. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. , 2010, Biochimica et biophysica acta.
[54] R Rowden,et al. The next decade. , 1993, Nursing times.